Boston/Shanghai/November 3rd, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mellitus (T2DM). This study will evaluate the safety,… Read More
— 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection — — BA.5 neutralizing antibody levels were approximately two to four-fold higher than BA.1 neutralizing antibody levels, demonstrating a potentially differentiated… Read More
— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents, consistent with results previously observed in adults — — Clover plans to submit adolescent data to… Read More
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study (NCT05431270) of PT199, an anti-CD73 monoclonal antibody (mAb) for the treatment of multiple advanced… Read More
Shanghai/August.1st, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants… Read More
First regulatory milestone as part of a strategy to advance patient care April 11, 2022 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that it has received 510(k) clearance from the U.S. Food and Drug… Read More
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties ADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway Cefepime/enmetazobactam has completed a Phase III clinical trial against standard of care in treating complicated urinary tract infection, including acute pyelonephritis1… Read More
MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a… Read More
Platform combines the innate immuno-stimulatory effect of the myxoma virus with anti-tumor immune stimulation that uniquely target multiple aspects of cancer immunity to treat solid tumors and hematological cancers OncoMyx is developing a next generation oncolytic virus platform including the capacity for multi-arming with a nonpathogenic virus which allows for… Read More
– Financing round was co-led by GordonMD Global Investment LP – Funding will support the Phase 2b clinical program of ATI-2173 in HBV MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the… Read More
